December 30, 2008

In Lieu of Falsies

Back in June, the maker of Botox was seeking FDA approval of its eyelash-boosting drug. Now, Allergan got its wish: the FDA has approved Latisse, an eyelash-thickening agent meant for people who have hypotrichosis of the eyelashes — in other words, too few lashes.

Latisse's active ingredient is bimatroprost, which happens to be the same ingredient used in glaucoma treatments. Side effects may include itchy eyes, eye redness, a change in skin color, and a potentially permanent darkening of the iris. (Ha--makes you want to run out and buy it, doesn't it?)

Posted by: Lawrenkm at 06:49 AM | No Comments | Add Comment
Post contains 100 words, total size 1 kb.

Comments are disabled. Post is locked.
11kb generated in CPU 0.02, elapsed 0.0911 seconds.
33 queries taking 0.0847 seconds, 118 records returned.
Powered by Minx 1.1.6c-pink.